组织蛋白酶k与骨质疏松症治疗的研究进展

Recent progress on the researches of cathepsin k and treatment of osteoporosis disease

组织蛋白酶k属于溶酶体半胱氨酸蛋白酶中的番木瓜蛋白酶超家族。人类缺失此蛋白酶会导致致密性成骨不全症(pyknodysostosis),它在多种病理现象中发挥作用,尤其是与骨质疏松症关系最为密切,是近年来备受关注的一类靶标蛋白酶。组织蛋白酶k的抑制剂可用于治疗骨质疏松症具有广阔的市场前景。笔者对组织蛋白酶k近年来在治疗骨质疏松的研究进展做一综述。

Cathepsin k belongs to the papain superfamily of lysosomal cystein protease, Human being will develop pycnodysostosis,if losing this gene. Cathepsin k has been implicated in various pathological settings, especially osteoporosis. So cathepsin k may represent important drug targets with more attention. Clinical researches show that the inhibitors of cathepsin k can be used to treat osteoporsis, therefore having wide potential market. This article reviews recent progress on the researches of cathepsin k and treatment of osteoporosis disease.